Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stake Boosted by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,160,565 shares of the company's stock after buying an additional 212,872 shares during the period. Federated Hermes Inc. owned approximately 3.05% of Zentalis Pharmaceuticals worth $32,733,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZNTL. Eventide Asset Management LLC lifted its holdings in Zentalis Pharmaceuticals by 13.6% in the third quarter. Eventide Asset Management LLC now owns 7,814,039 shares of the company's stock valued at $156,750,000 after acquiring an additional 936,236 shares during the period. Vanguard Group Inc. lifted its holdings in Zentalis Pharmaceuticals by 6.2% in the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company's stock valued at $105,047,000 after acquiring an additional 307,490 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Zentalis Pharmaceuticals by 2.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,298,551 shares of the company's stock valued at $120,789,000 after acquiring an additional 100,371 shares during the period. BlackRock Inc. lifted its holdings in Zentalis Pharmaceuticals by 15.6% in the second quarter. BlackRock Inc. now owns 3,950,804 shares of the company's stock valued at $111,452,000 after acquiring an additional 533,337 shares during the period. Finally, State Street Corp lifted its holdings in Zentalis Pharmaceuticals by 11.3% in the second quarter. State Street Corp now owns 3,152,914 shares of the company's stock valued at $88,944,000 after acquiring an additional 320,891 shares during the period.

Insider Activity at Zentalis Pharmaceuticals

In related news, CFO Melissa B. Epperly sold 2,573 shares of the business's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares of the company's stock, valued at approximately $5,164,576.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZNTL shares. Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a "neutral" rating in a report on Wednesday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $38.57.

Zentalis Pharmaceuticals Trading Up 3.3 %

Shares of NASDAQ:ZNTL traded up $0.42 during midday trading on Friday, hitting $12.96. 1,007,879 shares of the stock were exchanged, compared to its average volume of 629,397. The stock has a market cap of $919.64 million, a P/E ratio of -2.85 and a beta of 1.73. Zentalis Pharmaceuticals, Inc. has a twelve month low of $9.56 and a twelve month high of $31.46. The company has a 50 day moving average price of $14.09 and a 200-day moving average price of $14.05.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.09. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.